NeurogeneticsRett SyndromeHumansInsulin-Like Growth Factor IMethyl-CpG-Binding Protein 2Mutation
Mecasermin for the treatment of Rett Syndrome: a systematic review.
Fernanda Cristina Poscai Ribeiro, Maria Luiza Alves, Alice Campos Meneses, Áleff Mascarenhas Silva, Sabrine Zambiazi da Silva, Fabiana Khauam Marangoni, Kleber Fernando Pereira
Published: 202510.1007/s10048-025-00860-5
Abstract
Mecasermin, a recombinant analogue of insulin‑like growth factor 1 (IGF‑1), is under investigation as a potential therapy for Rett syndrome (RTT), a neurodevelopmental disorder resulting from mutations in the MECP2 gene. In this systematic review, we…
Preview only. Read the full abstract at the source